Insys Therapeutics, Inc. (NASDAQ:INSY) announced that the company will present at the 2014 UBS Global Healthcare Conference on May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City. Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will host the presentation on Tuesday, May 20, 2014 at 2:30 p.m. EDT. Insys Therapeutics Inc (NASDAQ:INSY) weekly performance is -19.01%. On last trading day company shares ended up $32.68. Analysts mean target price for the company is $62.00. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -23.67%.
Prima Biomed Ltd. (NASDAQ:PBMD) is surging 23.45% after the company announced that the United States Food and Drug Administration (“FDA”) granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission. Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S. Prima Biomed Ltd. (NASDAQ:PBMD) shares advanced 16.33% in last trading session and ended the day on $1.14. Prima Biomed Ltd. (NASDAQ:PBMD) quarterly performance is -18.57%.
Emergent Biosolutions Inc (NYSE:EBS) issued its quarterly earnings data on Thursday. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.41, Analyst RN reports. The company had revenue of $53.90 million for the quarter, compared to the consensus estimate of $57.30 million. Emergent Biosolutions Inc (NYSE:EBS) shares moved down -9.26% in last trading session and was closed at $22.73, while trading in range of $21.75 – $22.98 -. Emergent Biosolutions Inc (NYSE:EBS) year to date (YTD) performance is -1.13%.
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, reported first quarter 2014 financial results and provided an update on clinical progress. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) ended the last trading day at $1.02 . Company weekly volatility is calculated as 11.61% and price to cash ratio as 3.95. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) showed a positive weekly performance of 3.03%.